Aktienanalyse zu Olema Pharmaceuticals Inc (OLMA)OLMAOlema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its second product candidate in clinical development, called OP-3136, is a novel, orally available small molecule that potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Olema Pharmaceuticals is not a good buy right now due to its current price of $10.27, which is significantly lower than the average analyst price target of $46, indicating potential upside. However, the stock has a low RSI of 33.33, suggesting it is oversold, but the negative trend and increasing losses pose a risk. The main risk is the projected EPS for Q2 2026 of -0.61, which was worse than the estimate of -0.53, indicating ongoing financial struggles.